Rational design of 4-((6-phenoxypyrimidin-4-yl)amino)-N-(4-(piperazin-1-yl)phenyl)-1H-pyrazole-3-carboxamide (LT-540-717) as orally bioavailable FLT3 inhibitor
摘要:
we describe the discovery of compound LT-540-717 (32), a potent FLT3 inhibitor (IC50: 0.62 nM), starting from FN-1501. Compound 32 exhibited highly inhibitory activity against several acquired FLT3 mutations including FLT3 (ITD, D835V), FLT3 (ITD, F691L), FLT3 (D835Y) and FLT3 (D835V). Additionally, 32 displayed potentantiproliferativeactivity against FLT3-mutation driven BaF3 and AML cells. Oral administration
[EN] PYRIMIDINE COMPOUNDS AND THEIR USE<br/>[FR] COMPOSES PYRIMIDIQUES ET LEUR UTILISATION
申请人:SUMITOMO CHEMICAL CO
公开号:WO2002024663A2
公开(公告)日:2002-03-28
Pyrimidine compounds of formula (1), wherein R1 is C3-C7 alkynyl optionally substituted with halogen; R?2 and R3¿ are independently hydrogen or the like; and R4 is C3-C7 alkynyloxy optionally substituted with halogen, optionally substituted phenyl, or the like have an excellent pesticidal effect.